In the past week, CLOV stock has gone up by 10.11%, with a monthly decline of -13.72% and a quarterly plunge of -30.76%. The volatility ratio for the week is 6.18%, and the volatility levels for the last 30 days are 5.48% for Clover Health Investments Corp The simple moving average for the past 20 days is -0.16% for CLOV’s stock, with a -31.48% simple moving average for the past 200 days.
Is It Worth Investing in Clover Health Investments Corp (NASDAQ: CLOV) Right Now?
CLOV has 36-month beta value of 1.86. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CLOV is 376.56M, and currently, short sellers hold a 12.79% ratio of that float. The average trading volume of CLOV on April 29, 2024 was 9.30M shares.
CLOV) stock’s latest price update
The stock of Clover Health Investments Corp (NASDAQ: CLOV) has increased by 0.75 when compared to last closing price of 0.68.Despite this, the company has seen a gain of 10.11% in its stock price over the last five trading days. GlobeNewsWire reported 2024-04-23 that FRANKLIN, Tenn., April 23, 2024 (GLOBE NEWSWIRE) — Clover Health Investments, Corp. (NASDAQ: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that it will report first quarter 2024 financial results after market close on Tuesday, May 7, 2024. Management will host a conference call and webcast at 5:00 p.m. Eastern Time on May 7, 2024, to discuss the Company’s business and financial results.
Analysts’ Opinion of CLOV
Many brokerage firms have already submitted their reports for CLOV stocks, with Cowen repeating the rating for CLOV by listing it as a “Market Perform.” The predicted price for CLOV in the upcoming period, according to Cowen is $3 based on the research report published on February 02, 2022 of the previous year 2022.
Canaccord Genuity, on the other hand, stated in their research note that they expect to see CLOV reach a price target of $6. The rating they have provided for CLOV stocks is “Buy” according to the report published on February 02nd, 2022.
SVB Leerink gave a rating of “Mkt Perform” to CLOV, setting the target price at $3 in the report published on January 19th of the previous year.
CLOV Trading at -12.43% from the 50-Day Moving Average
After a stumble in the market that brought CLOV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -57.97% of loss for the given period.
Volatility was left at 5.48%, however, over the last 30 days, the volatility rate increased by 6.18%, as shares sank -11.56% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -32.60% lower at present.
During the last 5 trading sessions, CLOV rose by +9.40%, which changed the moving average for the period of 200-days by -30.41% in comparison to the 20-day moving average, which settled at $0.6818. In addition, Clover Health Investments Corp saw -28.04% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CLOV starting from Loengard Anna U, who purchase 137,000 shares at the price of $0.73 back on Mar 14 ’24. After this action, Loengard Anna U now owns 538,841 shares of Clover Health Investments Corp, valued at $100,010 using the latest closing price.
Loengard Anna U, the Director of Clover Health Investments Corp, purchase 13,625 shares at $0.73 during a trade that took place back on Mar 14 ’24, which means that Loengard Anna U is holding 15,125 shares at $9,946 based on the most recent closing price.
Stock Fundamentals for CLOV
Current profitability levels for the company are sitting at:
- -0.1 for the present operating margin
- 0.12 for the gross margin
The net margin for Clover Health Investments Corp stands at -0.11. The total capital return value is set at -0.67. Equity return is now at value -67.29, with -30.94 for asset returns.
Based on Clover Health Investments Corp (CLOV), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -24.85. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -29791.71.
Currently, EBITDA for the company is -180.16 million with net debt to EBITDA at 0.65. When we switch over and look at the enterprise to sales, we see a ratio of 0.11. The receivables turnover for the company is 17.82for trailing twelve months and the total asset turnover is 3.56. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.64.
Conclusion
To put it simply, Clover Health Investments Corp (CLOV) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
